



OPEN ACCESS

EDITED AND REVIEWED BY
Sophia George,
University of Miami, United States

*CORRESPONDENCE
Domenica Lorusso
✉ domenica.lorusso@policlinicogemelli.it

RECEIVED 31 May 2023
ACCEPTED 05 July 2023
PUBLISHED 07 August 2023

CITATION

Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Sabbatini R, Savarese A, Valabrega G, Zamagni C and Colombo N (2023) Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. *Front. Oncol.* 13:1232476. doi: 10.3389/fonc.2023.1232476

COPYRIGHT

© 2023 Lorusso, Danesi, Locati, Masi, De Giorgi, Gadducci, Pignata, Sabbatini, Savarese, Valabrega, Zamagni and Colombo. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

Domenica Lorusso^{1,2*}, Romano Danesi³, Laura Deborah Locati^{4,5}, Gianluca Masi^{6,7}, Ugo De Giorgi⁸, Angiolo Gadducci⁹, Sandro Pignata¹⁰, Roberto Sabbatini¹⁰, Antonella Savarese¹¹, Giorgio Valabrega¹², Claudio Zamagni¹³ and Nicoletta Colombo^{14,15}

¹Department of Clinical Research Planning, Fondazione Policlinico Universitario A Gemelli Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Rome, Italy, ²Department of Life Science and Public Health, Catholic University of Sacred Heart, Rome, Italy, ³Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴Translational Oncology Unit, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituti Clinici Scientifici (ICS) Maugeri, Pavia, Italy, ⁵Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy, ⁶Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁷Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, ⁸Department of Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy, ⁹Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy, ¹⁰Department of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricerca e Cura a carattere scientifico (IRCCS) "Fondazione Giovanni Pascale", Naples, Italy, ¹¹Division of Medical Oncology 1, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) -Regina Elena National Cancer Institute, Rome, Italy, ¹²University of Torino-Struttura Complessa a Direzione Universitaria (S.C.D.U.) Oncologia Azienda Ospedaliera (A.O) Ordine Mauriziano-Ospedale Umberto I, Torino, Italy, ¹³Addarii Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ¹⁴School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy, ¹⁵Department of Oncological Gynecology, European Institute of Oncology (IEO) Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Milan, Italy

KEYWORDS

lenvatinib, pembrolizumab, endometrial cancer, tyrosine kinase inhibitor, immune response

A corrigendum on

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

by Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Sabbatini R, Savarese A, Valabrega G, Zamagni C and Colombo N (2022) *Front. Oncol.* 12:979519. doi: 10.3389/fonc.2022.979519

In the published article, there was an error in [Figure 1](#) as published. By mistake, we added the reference 18 for this figure. The corrected [Figure 1](#) and its caption appear below.

In the published article, an author name was incorrectly written as Sabbatini Roberto. The correct name is Roberto Sabbatini.

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 1 Post hoc analysis of time to first onset of selected adverse reactions. Reproduced with permission from [19].